Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.
Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.
Expert Review of Clinical Pharmacology (ISSN 1751-2433) provides a forum for informed debate and critical analysis of all aspects of safety, tolerability, efficacy and therapeutic applications, in addition to covering toxicity issues, adverse reactions, pharmacoeconomics and societal issues.
Coverage includes:
• ADME studies and PK/PD modeling
• Novel clinical trial design and conduct
• Toxicity and carcinogenesis
• Adverse effects/reactions, drug–drug and drug–disease interactions
• Pharmacogenetics, genomics and the incorporation of new biomarkers in drug development and clinical practice
• Translational medicine
• Pharmacoepidemiology, risk management and pharmacovigilance
• Pharmacotherapy in specific patient groups, such as children, women, the immunocompromised
• Pharmacology and ethnicity
• Impact on quality of life and pharmacoeconomic issues
• Regulation of drug development and marketing
• Epidemiology and biostatistics
Expert Review of Clinical Pharmacology bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing clinical and pharmaceutical researchers, drug development specialists, physicians and other healthcare professionals with the key information they need to assist in the progress of pharmacological therapy.
All reviews are subject to rigorous peer review in association with our independent panel of Editorial Board members, representing the key experts in their pharmacological specialties.